Controlled release formulations of levodopa and uses thereof
602302 Disclosed is a controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, a decarboxylase inhibitor and one or more rate controlling excipients, b. a carboxylic acid component comprising a carboxylic acid that is not levodopa or th...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KOU JIM H ALANI LAMAN LYNN HSU ANN |
| description | 602302 Disclosed is a controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, a decarboxylase inhibitor and one or more rate controlling excipients, b. a carboxylic acid component comprising a carboxylic acid that is not levodopa or the decarboxylase inhibitor and one or more rate controlling excipients, and c. an immediate release component comprising levodopa and a decarboxylase inhibitor, wherein the carboxylic acid component of (b) is a distinct component and is coated with an enteric polymer; and wherein the controlled release component (a), the immediate release component (c) and the carboxylic acid component (b) comprise beads or granules; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with an enteric polymer; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d) , the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f). Further disclosed is a multiparticulate, controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, carbidopa and one or more rate controlling excipients; b. an immediate release component comprising levodopa and carbidopa, and c. a carboxylic acid component comprising a carboxylic acid that is not levodopa or carbidopa and one or more rate controlling excipients, wherein the carboxylic acid component of (c) is a distinct component and is coated with an enteric polymer and wherein the controlled release component (a), the immediate release component (b) and the carboxylic acid component (c) comprise beads or granules; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with an enteric polymer; and f. an imme |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NZ602302A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NZ602302A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NZ602302A3</originalsourceid><addsrcrecordid>eNqFyjEKAjEQBdA0FqJeQeYCwrILVjayKFZWVjbLYH5QGPNDJuv5beytXvOW4TAyt0ozRKkwqEMS63s2bS9mFyYxfBhZVDRHmR0u7YkKpnVYJDXH5ucqbM-n23jZoXCCF30go03X-77rh64_Dn_DFwjmLw4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Controlled release formulations of levodopa and uses thereof</title><source>esp@cenet</source><creator>KOU JIM H ; ALANI LAMAN LYNN ; HSU ANN</creator><creatorcontrib>KOU JIM H ; ALANI LAMAN LYNN ; HSU ANN</creatorcontrib><description>602302 Disclosed is a controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, a decarboxylase inhibitor and one or more rate controlling excipients, b. a carboxylic acid component comprising a carboxylic acid that is not levodopa or the decarboxylase inhibitor and one or more rate controlling excipients, and c. an immediate release component comprising levodopa and a decarboxylase inhibitor, wherein the carboxylic acid component of (b) is a distinct component and is coated with an enteric polymer; and wherein the controlled release component (a), the immediate release component (c) and the carboxylic acid component (b) comprise beads or granules; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with an enteric polymer; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d) , the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f). Further disclosed is a multiparticulate, controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, carbidopa and one or more rate controlling excipients; b. an immediate release component comprising levodopa and carbidopa, and c. a carboxylic acid component comprising a carboxylic acid that is not levodopa or carbidopa and one or more rate controlling excipients, wherein the carboxylic acid component of (c) is a distinct component and is coated with an enteric polymer and wherein the controlled release component (a), the immediate release component (b) and the carboxylic acid component (c) comprise beads or granules; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with an enteric polymer; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d), the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f). Further disclosed is a controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa and a decarboxylase inhibitor, wherein the component is coated with a rate controlling excipient, b. a carboxylic acid component coated with a rate controlling excipient, and c. an immediate release component comprising levodopa and a decarboxylase inhibitor, wherein the carboxylic acid component of (b) is a distinct component and wherein the carboxylic acid component (b) comprises a carboxylic acid that is not in (a) and (c) ; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with one or more enteric polymers; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d), the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f).</description><language>eng</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2014</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140430&DB=EPODOC&CC=NZ&NR=602302A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140430&DB=EPODOC&CC=NZ&NR=602302A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KOU JIM H</creatorcontrib><creatorcontrib>ALANI LAMAN LYNN</creatorcontrib><creatorcontrib>HSU ANN</creatorcontrib><title>Controlled release formulations of levodopa and uses thereof</title><description>602302 Disclosed is a controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, a decarboxylase inhibitor and one or more rate controlling excipients, b. a carboxylic acid component comprising a carboxylic acid that is not levodopa or the decarboxylase inhibitor and one or more rate controlling excipients, and c. an immediate release component comprising levodopa and a decarboxylase inhibitor, wherein the carboxylic acid component of (b) is a distinct component and is coated with an enteric polymer; and wherein the controlled release component (a), the immediate release component (c) and the carboxylic acid component (b) comprise beads or granules; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with an enteric polymer; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d) , the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f). Further disclosed is a multiparticulate, controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, carbidopa and one or more rate controlling excipients; b. an immediate release component comprising levodopa and carbidopa, and c. a carboxylic acid component comprising a carboxylic acid that is not levodopa or carbidopa and one or more rate controlling excipients, wherein the carboxylic acid component of (c) is a distinct component and is coated with an enteric polymer and wherein the controlled release component (a), the immediate release component (b) and the carboxylic acid component (c) comprise beads or granules; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with an enteric polymer; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d), the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f). Further disclosed is a controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa and a decarboxylase inhibitor, wherein the component is coated with a rate controlling excipient, b. a carboxylic acid component coated with a rate controlling excipient, and c. an immediate release component comprising levodopa and a decarboxylase inhibitor, wherein the carboxylic acid component of (b) is a distinct component and wherein the carboxylic acid component (b) comprises a carboxylic acid that is not in (a) and (c) ; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with one or more enteric polymers; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d), the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f).</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2014</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFyjEKAjEQBdA0FqJeQeYCwrILVjayKFZWVjbLYH5QGPNDJuv5beytXvOW4TAyt0ozRKkwqEMS63s2bS9mFyYxfBhZVDRHmR0u7YkKpnVYJDXH5ucqbM-n23jZoXCCF30go03X-77rh64_Dn_DFwjmLw4</recordid><startdate>20140430</startdate><enddate>20140430</enddate><creator>KOU JIM H</creator><creator>ALANI LAMAN LYNN</creator><creator>HSU ANN</creator><scope>EVB</scope></search><sort><creationdate>20140430</creationdate><title>Controlled release formulations of levodopa and uses thereof</title><author>KOU JIM H ; ALANI LAMAN LYNN ; HSU ANN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NZ602302A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2014</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>KOU JIM H</creatorcontrib><creatorcontrib>ALANI LAMAN LYNN</creatorcontrib><creatorcontrib>HSU ANN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KOU JIM H</au><au>ALANI LAMAN LYNN</au><au>HSU ANN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Controlled release formulations of levodopa and uses thereof</title><date>2014-04-30</date><risdate>2014</risdate><abstract>602302 Disclosed is a controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, a decarboxylase inhibitor and one or more rate controlling excipients, b. a carboxylic acid component comprising a carboxylic acid that is not levodopa or the decarboxylase inhibitor and one or more rate controlling excipients, and c. an immediate release component comprising levodopa and a decarboxylase inhibitor, wherein the carboxylic acid component of (b) is a distinct component and is coated with an enteric polymer; and wherein the controlled release component (a), the immediate release component (c) and the carboxylic acid component (b) comprise beads or granules; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with an enteric polymer; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d) , the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f). Further disclosed is a multiparticulate, controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa, carbidopa and one or more rate controlling excipients; b. an immediate release component comprising levodopa and carbidopa, and c. a carboxylic acid component comprising a carboxylic acid that is not levodopa or carbidopa and one or more rate controlling excipients, wherein the carboxylic acid component of (c) is a distinct component and is coated with an enteric polymer and wherein the controlled release component (a), the immediate release component (b) and the carboxylic acid component (c) comprise beads or granules; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with an enteric polymer; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d), the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f). Further disclosed is a controlled release oral solid formulation of levodopa comprising: a. a controlled release component comprising levodopa and a decarboxylase inhibitor, wherein the component is coated with a rate controlling excipient, b. a carboxylic acid component coated with a rate controlling excipient, and c. an immediate release component comprising levodopa and a decarboxylase inhibitor, wherein the carboxylic acid component of (b) is a distinct component and wherein the carboxylic acid component (b) comprises a carboxylic acid that is not in (a) and (c) ; with the proviso that the controlled release oral solid formulation is not: a multiparticulate, controlled release oral solid formulation of levodopa comprising: d. a controlled release component comprising a core of levodopa and carbidopa which is coated with one or more enteric polymers; e. a carboxylic acid component which is coated with one or more enteric polymers; and f. an immediate release component comprising a mixture of levodopa and carbidopa, wherein the controlled release component (d), the carboxylic acid component (e) and the immediate release component (f) are distinct, separable beads or granules; and wherein the carboxylic acid component (e) comprises a carboxylic acid that is not in (d) and (f).</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_NZ602302A |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY METALLURGY ORGANIC CHEMISTRY |
| title | Controlled release formulations of levodopa and uses thereof |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A49%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KOU%20JIM%20H&rft.date=2014-04-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENZ602302A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |